Next Article in Journal / Special Issue
Biomarkers for Basal-like Breast Cancer
Previous Article in Journal
Molecular Mechanisms Involved in the Antitumor Activity of Cannabinoids on Gliomas: Role for Oxidative Stress
Previous Article in Special Issue
Predictive and Prognostic Protein Biomarkers in Epithelial Ovarian Cancer: Recommendation for Future Studies
Cancers 2010, 2(2), 1027-1039; doi:10.3390/cancers2021027
Review

Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies

*  and
Received: 29 March 2010; in revised form: 11 May 2010 / Accepted: 27 May 2010 / Published: 28 May 2010
(This article belongs to the Special Issue Biomarkers: Oncology Studies)
View Full-Text   |   Download PDF [343 KB, uploaded 28 May 2010]
Abstract: The dependence of tumor growth and metastasis on blood vessels makes tumor angiogenesis a rational target for therapy. Strategies have been pursued to inhibit neovascularization and to destroy existing tumor vessels, or both. These include direct targeting of endothelial cells, and indirect targeting by inhibiting the release of proangiogenic growth factors by cancer or stromal cells. Many patients benefit from antiangiogenic therapies; thus, development of noninvasive biomarkers of disease response and relapse is a crucial objective to aid in their management. A number of non-invasive tools are described with their potential benefits and limitations. We review currently available candidate biomarkers of anti-angiogenic agent effect. Including these markers into clinical trials may provide insight into appropriate dosing for desired biological effects, appropriate timing of additional therapy, and prediction of individual response. This has important consequences for the clinical use of angiogenesis inhibitors and for drug discovery, not only for optimizing the treatment of cancer, but possibly also for developing therapeutic approaches for various other diseases.
Keywords: cancer; angiogenesis; biomarkers cancer; angiogenesis; biomarkers
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Rabascio, C.; Bertolini, F. Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies. Cancers 2010, 2, 1027-1039.

AMA Style

Rabascio C, Bertolini F. Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies. Cancers. 2010; 2(2):1027-1039.

Chicago/Turabian Style

Rabascio, Cristina; Bertolini, Francesco. 2010. "Blood-Based Biomarkers for the Optimization of Anti-Angiogenic Therapies." Cancers 2, no. 2: 1027-1039.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert